美国食品和药物管理局批准Addyi用于经更年期妇女的性欲低. 
FDA approves Addyi for postmenopausal women with low sexual desire.
美国林业发展局扩大了对Addyi的核准范围,将65岁以下更年期后妇女也包括在内。 Addyi是针对妇女性欲低的日常避孕药。 The U.S. FDA has expanded approval of Addyi, a daily pill for low sexual desire in women, to include postmenopausal women up to age 65. 该药物最初于2015年被批准用于绝经前妇女,但因成效不高和副作用,如头晕和恶心,同时受到一箱警告,警告在与酒精结合时会出现危险的血压下降。 Originally approved in 2015 for premenopausal women, the drug has faced scrutiny over modest effectiveness and side effects like dizziness and nausea, along with a boxed warning about dangerous blood pressure drops when combined with alcohol. 在经过多年的宣传和研究之后,这一批准标志着在解决女性性健康方面迈出了重要一步,尽管医疗界在是否将低性欲归类为医疗状况的问题上仍然意见不一。 The approval follows years of advocacy and research, marking a significant step in addressing female sexual health, though the medical community remains divided on whether low libido should be classified as a medical condition. 2019年核准了对低女性性欲的第二次治疗。 A second treatment for low female libido was approved in 2019.
